Phosphodiesterase-5 Inhibition Alleviates Pulmonary Hypertension and Basal Lamina Thickening in Rats Challenged by Chronic Hypoxia. by Nydegger, C. et al.
ORIGINAL RESEARCH
published: 27 March 2018
doi: 10.3389/fphys.2018.00289
Frontiers in Physiology | www.frontiersin.org 1 March 2018 | Volume 9 | Article 289
Edited by:
Pasquale Pagliaro,
Università degli Studi di Torino, Italy
Reviewed by:
Valentina Mercurio,
University of Naples Federico II, Italy
Guido Iaccarino,
Università degli Studi di Salerno, Italy
*Correspondence:
Giuseppina Milano
giuseppina.milano@chuv.ch
Specialty section:
This article was submitted to
Vascular Physiology,
a section of the journal
Frontiers in Physiology
Received: 09 January 2018
Accepted: 12 March 2018
Published: 27 March 2018
Citation:
Nydegger C, Martinelli C, Di Marco F,
Bulfamante G, von Segesser L,
Tozzi P, Samaja M and Milano G
(2018) Phosphodiesterase-5 Inhibition
Alleviates Pulmonary Hypertension
and Basal Lamina Thickening in Rats
Challenged by Chronic Hypoxia.
Front. Physiol. 9:289.
doi: 10.3389/fphys.2018.00289
Phosphodiesterase-5 Inhibition
Alleviates Pulmonary Hypertension
and Basal Lamina Thickening in Rats
Challenged by Chronic Hypoxia
Coline Nydegger 1, Carla Martinelli 2, Fabiano Di Marco 2,3, Gaetano Bulfamante 2,3,
Ludwig von Segesser 1, Piergiorgio Tozzi 1, Michele Samaja 2 and Giuseppina Milano 1*
1 Laboratory of Cardiovascular Research, Department of Surgery and Anesthesiology, University Hospital of Lausanne,
Lausanne, Switzerland, 2Department of Health Science, University of Milan, Milan, Italy, 3 ASST Santi Paolo e Carlo, Milan,
Italy
Background: Hypoxia represents both an outcome of cardiopulmonary diseases and
a trigger for severe pulmonary complications as pulmonary hypertension. Because
nitric oxide (NO) is a critical mediator in the development of pulmonary hypertension,
the modulators of its downstream function may become target of pharmacological
interventions aimed at alleviating the impact of this condition. Here, we investigate
the effects of an early administration of phosphodiesterase-5 inhibitor in rats where
pulmonary artery hypertension was induced by chronic exposure to hypoxia.
Methods: Rats were divided into three groups: normoxic control, hypoxic with no
treatments (2 weeks breathing an atmosphere containing 10% oxygen), and hypoxic
treated with sildenafil (1.4 mg/Kg per day in 0.3mL i.p.). After sacrifice, hearts and lungs
were removed and harvested for analyses.
Results: Sildenafil reduced hypoxia-induced right ventricle hypertrophy without effects
in lung hypertrophy, and blunted the increase in right ventricle pressure without effects on
left ventricle pressure. Furthermore, the NO-producing systems (i.e., the phosphorylation
of the endothelial isoforms of NO synthase that was measured in both myocardial and
lung tissues), and the blood NO stores (i.e., the plasma level of nitrates and nitrites)
were up-regulated by sildenafil. We did not find significant effects of sildenafil on weight
and hemoglobin concentration. Morphological analysis in lung biopsies revealed that 2-
week hypoxia increased the frequency of small pulmonary vessels leaving large vessels
unaffected. Finally, ultrastructural analysis showed that sildenafil down-regulated the
hypoxia-induced increase in the thickness of the pulmonary basal lamina.
Conclusions: In this model of pulmonary hypertension, sildenafil contrasts the negative
effects of hypoxia on pulmonary vascular and right ventricle remodeling. This action
does not only encompass the canonical vasomodulatory effect, but involves several
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biochemical pathways. Although the human pathological model is certainly more
complex than that described here (for example, the inflammatory issue), the potential role
of phosphodiesterase-5 for long-term treatment, and perhaps prevention, of pulmonary
hypertension is worthy of investigation.
Keywords: pulmonary hypertension, nitric oxide, phosphodiesterase 5, sildenafil, right heart failure, nitrites and
nitrates, endothelial NO synthase, pulmonary vascular remodeling
INTRODUCTION
Pulmonary hypertension (PH), a devastating complication of
several cardiopulmonary diseases such as chronic heart failure
(CHF) and chronic obstructive pulmonary disease (COPD),
arises from the progressive narrowing or destruction of the
arteries that carry blood from the heart to the lungs. The raise
in pulmonary arteries pressure strains the right ventricle (RV)
causing hypertrophy and eventually leading to right heart failure.
This pathobiology is complicated by hypoxia, which is at the same
time an outcome of pulmonary diseases and an established trigger
for PH as it was reported, for example, in rats breathing 10%
O2 for 2 weeks, which develop marked signs of RV hypertrophy
(Milano et al., 2011). Impaired nitric oxide (NO) bioavailability
is a key feature in most forms of clinical and experimental PH
(Giaid and Saleh, 1995; Bueno et al., 2013). Classically, NO is
believed to modulate the vascular function through stimulation
of smooth muscle cell soluble guanylate cyclase that catalyzes
the conversion of guanosine triphosphate into cyclic guanosine
monophosphate (cGMP), which lowers cytoplasmic Ca2+ and
mediates smooth muscle cell relaxation. Pharmacologically, this
effect can be made more persistent and intense by selective
inhibitors of phosphodiesterase type 5 (PDE5), an enzyme
that degrades cGMP into inactive 5′GMP. The best known
example of these inhibitors, sildenafil surged as a drug able
to alleviate symptoms in several cardiopulmonary diseases
including pulmonary arterial hypertension (PAH) (Guazzi and
Samaja, 2007) and to correct hypoxia-induced RV hypertrophy
(Milano et al., 2011). The underlying scenario reflects a situation
where the sildenafil-induced increase in cGMP levels upregulates
the phosphorylation of the endothelial isoform of NOS (eNOS),
which increases the phosphorylation of Akt, thereby mitigating
apoptosis in cardiomyocytes. Although we are far from definite
data due to the controversy of available results, in some cases the
administration of sildenafil revealed to be useful for the treatment
of cardiac heart failure devoid of remarkable adverse effects
(Guazzi et al., 2007). The same NO/cGMP pathway is used by
the drug riociguat that stimulates the activity of soluble guanylate
cyclase independently of NO and acts in synergy with NO to
produce anti-proliferative and vasodilatory effects (Lang et al.,
2012). However, sildenafil may also have effects not mediated
Abbreviations: PD, chronic obstructive pulmonary disease. eNOS, endothelial
isoform of NO synthase. LV, left ventricle. LVSP, LV systolic pressure. NO, nitric
oxide, NOx, nitrates and nitrites. PAH, pulmonary arterial hypertension. PDE-5,
phosphodiesterase-5. p-eNOS, phosphorylated isoform of eNOS. PH, pulmonary
hypertension. RV, right ventricle. RVSP, RV systolic pressure. TEM, transmission
electron microscope. VEGF, vascular endothelial factor. VEGFR1, receptor of
VEGF.
by modulation of vasoconstriction, and in lungs it has been
shown to improve pulmonary hemodynamic by modulating the
recruitment of bone marrow-derived c-kit+ cells (Favre et al.,
2017).
The basal lamina, a layer of extracellular matrix secreted
by epithelial cells, acts both as an attachment point for cells
and as a permeability barrier. Degenerative pathologies like
diabetes mellitus, but also primary respiratory diseases such
as asthma and COPD, are known to induce a thickening of
the pulmonary basal lamina (Weynand et al., 1999; Liesker
et al., 2009), whose thickness represents a compromise between
two opposite needs, providing mechanical resistance against
excessive pressure buildup, and facilitating the diffusion of
gasses across the alveolar-capillary barrier (West and Mathieu-
Costello, 1999). This compromise may be overruled in several
instances, and hypoxia-induced pulmonary edema has been
attributed to stress failure of pulmonary capillaries, which may
be due by un-matching the delicate balance between basal lamina
strengthening and increased pulmonary hypertension (West
et al., 1995). However, direct measurement of the basal lamina
thickness as a function of hypoxia is still lacking, consequently it
may become difficult to assess whether acute alterations of the
thickness and strength of the basal lamina may make part of
hypoxia adaptation and pulmonary hypertension development.
Aim of this study was to test the impact of sildenafil, a
PDE5 inhibitor, on right heart and pulmonary vessels in an
experimental model of hypoxia-induced PH.
METHODS
Animal Experiments
We used 42 male 8-week old Sprague-Dawley rats (200–
250 g initial nominal weight). Rats were randomly divided into
three groups: control, exposed to hypoxia (10% O2) for 2
weeks, and exposed to hypoxia and treated with sildenafil (1.4
mg/Kg per day in 0.3mL i.p.). Each group was composed
of two subgroups of 6 rats/each. Rats from the first and
second subgroup were used for morphometry/hemodynamics,
and biochemical measurements, respectively. Hypoxia was
administered in specially designed chambers that enable all
treatments, including drug administration and animals handling,
avoiding any exposure of animals to atmospheric air (Milano
et al., 2002, 2004). Sacrifice was performed 24 h after the last
administration. Rats were anesthetized (80 mg/kg xylazine, 100
mg/kg ketasol and 1,500 IU heparin i.p.) in the compensation
chamber kept at 10% O2. This study was carried out in
accordance with the recommendations of the National Institutes
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of Health (NIH Publication No. 85–23, Revised 1996). The
protocol was approved y the Government Veterinary Office
(Lausanne, Switzerland; authorization Nr VD2467.1).
Hemodynamic Monitoring
At the end of study, the left ventricle (LV) and right ventricle
(RV) systolic pressures (RVSP and LVSP, respectively) were
measured by placing a Millar Mikro-Tip conductance catheter
(SPR-838, 2F catheter, Millar Instruments Inc., Oxford, UK,
coupled to a MPVS Ultra system Millar Instruments, Oxford,
UK) as described (Favre et al., 2017). Briefly, anesthetized rats
were placed on a heating pad at 37◦C and ventilated at 50
cycles·min−1 with a tidal volume of 2.5ml (Harvard Apparatus
model 683, Holliston, MA, USA) with either room air or hypoxic
atmosphere for normoxic and hypoxic groups, respectively. To
evaluate the LVPS, theMillar catheter was introduced into the LV
via right carotid artery. To evaluate the RVSP, the chest cavity was
opened and the Millar catheter was introduced in the RV cavity
using a 24-gauge needle.
Blood Measurements
A blood sample was taken into heparinized tubes after euthanasia
from the descending abdominal aorta for measurement of
blood hemoglobin (Servomex Oxygen Analyzer 570A, Zurich,
Switzerland) and plasma nitrates and nitrites (colorimetric Griess
reaction).
Animal Sacrifice and Pulmonary and
Cardiac Hypertrophy
After the hemodynamic measurements, lungs and hearts were
perfused en-block with PBS via the RV with eﬄux through a
small opening in the left atrium as reported (Favre et al., 2017).
Then, lungs and hearts were placed in PBS solution and kept
on ice. After removing the atria from the ventricles, the RV
was separated from the LV and the septum (S), blotted dry and
weighed to obtain the ratio of RV/(LV+S).
Pulmonary Vascular Remodeling
The degree of muscularization of pulmonary arterioles was
assessed from immunohistochemical staining of the small
pulmonary artery, as previously described (Favre et al., 2017).
Briefly, paraffin-embedded lungs were serially sectioned at 8µm
thickness. Following citrate-based antigen retrieval, the sections
were blocked with 5% (v/v) goat serum for 1 h. Then, sections
were incubated with an antibody against smooth muscle α-
actin (α-SMA 1:250, clone 1A4, Sigma-Aldrich) overnight at
4◦C, followed by a goat anti-mouse IgG secondary antibody
(1/500, DAKO). Pulmonary arterioles were divided by outer
vessel diameter in four categories: small (0–50µm), medium
(50–100µm), large (100–200µm) and very large (>200µm)
diameters. Pulmonary vascular remodeling was assessed by the
percent medial wall thickness. Ten vessels were analyzed for each
rat, in seven rats per group per time-point, except for very large
(>200µm) vessels, where the number of analyzed vessels was
2–3. Morphological analyses were conducted in a double-blind
method.
Protein Extraction and Western Blot
Analysis
In a subset of experiment animals, standard Western blotting
analysis was performed using lung and cardiac lysates, as
described previously (Favre et al., 2017). The membranes
were incubated overnight at 4◦C with antibodies against p-
eNOS (Ser1177, 1:1,000, Cell Signaling Technology) and e-NOS
(1:1,000, Santa Cruz Biotechnology, Santa Cruz). Secondary
HRP-conjugated antibodies were applied for 1 h at room
temperature (1:4,000). Signals were detected by using the
enhanced chemiluminescence system (Amersham, Arlington
Heights, IL, USA) of a commercial ECL kit. Quantification of the
band intensities was performed using NIH ImageJ.
ELISA
VEGF and VEGF-R1 protein levels were quantified in lung
lysates by ELISA (ELISA kit, Assay Designs, Inc., MI). All
assays were made in duplicate and performed according to the
manufacturer’s instruction.
RT-PCR
Total RNA of lung tissues was extracted using the TRIzol method
as described (Favre et al., 2017). The relative amount of mRNA
expression for vascular endothelial growth factor (VEGF) was
represented using the 2-11Ct value. The primer pairs for VEGF
(109 bp) were designed (sense: 5′ -AGTACCTGTTCTGGCTAA
TGG-3′; anti-sense: 5′-TCACTTTCGTGCGCTCGTAG-3′) and
TABLE 1 | Whole animal data expressed as mean ± SEM.
Normoxia Hypoxia Hypoxia + sildenafil 1-way
ANOVA
Body weight initial, g 248.1 ± 3.0 246.5 ± 8.5 254.5 ± 9.1 NS
Body weight final, g 340.3 ± 7.9 252.2 ± 10.4§ 271.8 ± 5.1§ <0.0001
Heart weight, g 1.303 ± 0.047 1.383 ± 0.058 1.161 ± 0.054 0.0484
Lungs weight, g 1.545 ± 0.071 1.990 ± 0.058§ 1.957 ± 0.063§ <0.0001
Hematocrit, % 50.7 ± 1.5 66.0 ± 2.4§ 64.7 ± 1.3§ <0.0001
Hemoglobin, g/L 158.18 ± 3.58 200.25 ± 7.25§ 201.53 ± 5.15§ <0.0001
RBC/fl 8.65 ± 0.36 10.45 ± 0.43§ 10.05 ± 0.29§ <0.0001
§P < 0.05 vs. normoxia (Tukey’s multiple comparison test). No significant differences have been observed between hypoxia and hypoxia + sildenafil.
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FIGURE 1 | Effects of 2-week hypoxia (10% O2) and hypoxia + sildenafil on
the heart/body weight ratio, right ventricle hypertrophy, lung/body weight ratio,
and number of vessels in the right lung. Data are expressed as mean ± SEM.
The 1-way ANOVA value is reported for each variable. $P < 0.05 vs.
normoxia, §P < 0.05 between hypoxia and hypoxia + sildenafil (Tukey’s
multiple comparison test).
for the housekeeping gene GAPDH (359 bp) were (forward) 5′-T
GAAGGTCGGTGTGAACGGATTTG-3′ and (reverse) 5′-GGC
GGAGATGATGACCCTTTTG-3′, respectively.
Transmission Electron Microscopy (TEM)
Lung biopsies were fixed in 2.5% (v/v) glutaraldehyde dissolved
in 0.13M phosphate buffer (pH 7.2–7.4). Five specimens for
each biopsy were post-fixed in 1% OsO4, dehydrated in ethanol
plus propylene oxide and embedded in epoxy resin. Ultrathin
50–60 nm sections were routinely counterstained with uranyl
acetate (10min, Merck, Darmstadt, Germany) and lead citrate
(5min, Merck, Darmstadt, Germany), and examined with a JEM
1010 (Jeol, Tokyo, Japan) electron microscope. To determine the
median basal lamina thickness, the Marquez simplified method
FIGURE 2 | Effects of 2-week hypoxia (10% O2) and hypoxia + sildenafil on
the pressures developed by the left and right ventricles. Data are expressed as
mean ± SEM. The 1-way ANOVA value is reported for each variable.
$P < 0.05 vs. normoxia, §P < 0.05 between hypoxia and hypoxia + sildenafil
(Tukey’s multiple comparison test).
was applied in printed 18 × 24 cm micrographs taken at 24,000
×magnification using 10 areas at a fixed 4mm distance from one
to another. The average thickness measured in the 10 areas was
considered as the final value. To determine the mitochondrial
size, the areas of 30 randomly selected mitochondria for each
condition was calculated.
Statistics
Data are expressed as mean ± SEM. To measure the effects
of hypoxia and sildenafil, we performed one-way analysis of
variance followed by the Tukey’s multiple comparison test if
significant. The significance level was set at P = 0.05.
RESULTS
Whole Animal Data
All animals survived the experimental protocol without signs of
discomfort. Whole animal data are reported in Table 1. Exposure
to hypoxia for 2 weeks decreased body weight. Likewise, hypoxia
increased blood hemoglobin, hematocrit and red cell count. No
changes were observed in heart weight, but hypoxia increased the
wet weight in both lungs. None of these variables was affected by
sildenafil.
Sildenafil Reduced Hypoxia-Induced Right
Ventricle Hypertrophy Without Effects in
Lung Morphology
Although the heart weight was apparently unaffected by neither
hypoxia, nor sildenafil, the simultaneous decrease in body
weight led to varied heart/body weight ratios, which is an
index of myocardial hypertrophy (Figure 1). This ratio increased
markedly in untreated rats upon hypoxia, but the administration
of sildenafil markedly blunted this effect. The RV/(LV+S) ratio is
a reliable index of RV hypertrophy. This ratio increasedmarkedly
after 2-week hypoxia, but the increase was less in sildenafil-
treated rats. The lung/body wet weight was also markedly
increased by hypoxia, and sildenafil was unable to alleviate
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FIGURE 3 | Effects of 2-week hypoxia (10% O2) and hypoxia + sildenafil on the wall thickness of small (0–50µm), medium (50–100µm), large (100–200µm), and
very large (>200µm) pulmonary vessels determined as explained in the Materials and Methods section. The lower row shows representative images taken from each
group. Notations (A-C) refer to normoxia, hypoxia, and hypoxia + sildenafil, respectively. The bar represents 100µm. Data are expressed as mean ± SEM. The 1-way
ANOVA value is reported for each variable. $P < 0.05 vs. normoxia, §P < 0.05 between hypoxia and hypoxia + sildenafil (Tukey’s multiple comparison test).
this increase. Likewise, the number of vessels in the right lung
increased during hypoxia and sildenafil corrected this increase.
Sildenafil Blunted the Increase in Right
Ventricle Pressure Without Effects on Left
Ventricle Pressure
Figure 2 shows the left and right ventricle pressure as measured
as explained in the Materials and Methods section. The pressure
developed by the left ventricle was not affected by neither
hypoxia nor sildenafil. By contrast, the pressure developed by
the right ventricle was increased by hypoxia, indicative of PAH
development. This increase was markedly blunted in sildenafil-
treated rats.
Two-Week Hypoxia Increases the
Frequency of Small Pulmonary Vessels
Leaving Large Vessels Unaffected
As shown in Figure 1, hypoxia increased the number of
pulmonary vessels. To ascertain whether this increase was
shared to both newly formed and mature vessels, we measured
the frequency of vessels in four categories of wall thickness,
arbitrarily divided into small (0–50µm), medium (50–100µm),
large (100–200µm), and very large (>200µm) diameters
(Figure 3). It appears that the effect of hypoxia was more
pronounced for small vessels and progressively diminished with
the vessels diameter. As a result, the anti-hypoxic effect of
sildenafil was more marked in small than in large vessels. The
frequency of very large vessels was unaffected by either hypoxia
or sildenafil.
NO-producing Systems Are Up-Regulated
by Sildenafil
The p-eNOS/eNOS ratio highlights the activation of NO-
producing enzymes. In both heart and lung biopsies,
hypoxia decreased this ratio, while sildenafil promoted eNOS
phosphorylation (Figure 4). The plasma level of nitrates and
nitrites (NOx) marks the NO stores level. While hypoxia
produced an increase in plasma NO stores, sildenafil was able to
further increases it. However, neither hypoxia nor sildenafil were
able to affect none of the factors linked to the vascular endothelial
growth factor (VEGF). Indeed, the protein expression of VEGF
and VEGF-R, as well as VEGF mRNA remained constant in the
three groups.
Sildenafil Efficiently Down-Regulates the
Hypoxia-Induced Increase in the Thickness
of the Pulmonary Basal Lamina
Figure 5 shows some representative electron microscope images
highlighting the effects of 2-week hypoxia (10%O2) and sildenafil
on mitochondrial size and the thickness of the basal lamina.
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FIGURE 4 | Effects of 2-week hypoxia (10% O2) and hypoxia + sildenafil on the phosphorylation and activation of NO-generating enzymes as well as on the level of
nitrites and nitrates in plasma (Upper row), and VEGF-related parameters (Lower row). Data are expressed as mean ± SEM. The 1-way ANOVA value is reported
for each variable. $P < 0.05 vs. normoxia, §P < 0.05 between hypoxia and hypoxia + sildenafil (Tukey’s multiple comparison test).
Averaged data obtained in all available samples are shown on
the right panel. As expected, hypoxia increased themitochondrial
size, and sildenafil contrasted this effect. Likewise, while hypoxia
increased the thickness of the basal lamina, sildenafil down-
regulated this increase.
DISCUSSION
In this study, we report some cardiopulmonary responses to 2-
week chronic hypoxia. The severity of the hypoxia challenge, 10%
O2, is known to induce molecular and cellular alterations without
becoming lethal even after 4 weeks inmice (Terraneo et al., 2017).
In the rat, breathing 10% O2 for 2 weeks impairs the myocardial
tolerance to ischemia/reperfusion (Milano et al., 2002), induces
RV hypertrophy (Corno et al., 2004), impairs K+ATP channels
opening (Milano et al., 2004), activates hypoxic signaling and
apoptosis (Bianciardi et al., 2006), modulates differentially the
expression of mitogen-activated protein kinases (Caretti et al.,
2007) and increases the immunoreactivity against the 70 kDa
heat shock proteins (Tarricone et al., 2008). Furthermore, 2-
week hypoxia also reduces the myocardial p-eNOS/eNOS ratio
while increasing plasma NOx in a mechanism resembling that
underlying intermittent hypoxia (Milano et al., 2010, 2011).
Here, we show that most of the hypoxia-induced changes that
regard NO handling in the lungs may be strongly modulated by
sildenafil.
Despite its short plasma half-life of sildenafil of 4–6 h
(Boolell et al., 1996), the selected dose and timing for sildenafil
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FIGURE 5 | Effects of 2-week hypoxia (10% O2) and hypoxia + sildenafil on mitochondrial size and the thickness of the pulmonary basal lamina. Two representative
micrographs for each group are displayed. Notations (A-C) refer to normoxia, hypoxia, and hypoxia + sildenafil, respectively. Arrows indicate the basal lamina, while
the notation M indicates the mitochondria (scale bars = 0.5µm). Averaged data on the right panel are expressed as mean ± SEM. The 1-way ANOVA value is
reported for each variable. $P < 0.05 vs. normoxia, §P < 0.05 between hypoxia and hypoxia + sildenafil (Tukey’s multiple comparison test).
administration was already shown to be sufficient to enable
sildenafil to hit its target by inducing a x4 increase in cGMP
in heart tissue (Milano et al., 2011). Sildenafil was shown to
protect tissue by elevating the protein level of both iNOS
and eNOS (Salloum et al., 2003). The activation of the NO-
producing system by eNOS Ser1177 phosphorylation was reported
to be a key step through which sildenafil exerts cardioprotective
effects in chronically hypoxic hearts (Baker et al., 2001) by
reducing apoptosis, enhancing protein kinase B activation
(Milano et al., 2011), down-regulating intracellular calcium
by mitochondrial K+ATP channels opening (Fitzpatrick et al.,
2005), and attenuating the recruitment of bone-marrow-derived
c-kit(+) cells (Favre et al., 2017). Remarkably, we were unable
to document a similar effect on VEGF and VEGF-R1 expression
that were reviewed to be upregulated by sildenafil in an attempt to
improve angiogenesis to restore the hypoxia-challenged viability
(Liu and Simon, 2004). However, the situation in lungs that are
exposed directly to atmospheric air may be quite different from
that in other internal organs where angiogenesis is the key way to
transfer the oxygen brought by capillary blood. Because sildenafil
did not affect the blood hemoglobin concentration, the increased
activation of eNOS reflects into higher plasma NO stores or NOx.
The total number of vessels in both lungs appear to follow
the same pattern described for eNOS phosphorylation and NO
stores: whereas exposure to hypoxia increases the value, the
administration of sildenafil can markedly reduce, and sometimes
blunt, such increase. However, the changes in size distribution
of pulmonary vessels is dependent on the vessel diameter. Small
pulmonary vessels are strongly affected by hypoxia and by
sildenafil. By contrast, larger pulmonary vessels are less affected
by hypoxia and sildenafil. If the size of the pulmonary vessels
is associated with their degree of maturation, then this may be
attributed to the vessel maturation process. The thickness of the
basal lamina may be another key to understand the effects of
PDE-5 inhibition in lungs. As mentioned above, the pulmonary
blood-gas barrier represents a compromise between two opposite
needs: a reduced thickness favors oxygen diffusion, while its
increase contributes to strengthen the barrier. If hypoxia involves
high RVSP, and sildenafil reduces it, this translates into less
demand to improve pulmonary resistance against circulatory
stress by tightening the basal lamina, thus favoring oxygen
diffusion. As such, sildenafil may be considered an “anti-hypoxic”
drug.
PH is an important complication in the natural history
of cardiopulmonary diseases, such as COPD. Its presence is
associated with reduced survival and greater use of healthcare
resources. In COPD, pulmonary vascular remodeling, due to
inflammation and/or hypoxia, affects small and precapillary
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arteries, and has been identified at different degrees of disease
severity. Patients with end-stage COPD and PH show deposition
of longitudinal muscle, fibrosis and elastosis that enlarge the
intima in pulmonary muscular arteries (Barberà and Blanco,
2009). Impairment of endothelial function may be associated
with or result from changes in the expression or balanced release
of vasoactive mediators with vasodilator properties, such as NO
or prostacyclin, and mediators with vasoconstrictive properties,
such as endothelin-1 or angiotensin. Indeed, eNOS expression
in pulmonary arteries, which is diminished in patients with
idiopathic PAH (Giaid and Saleh, 1995) is also reduced in
COPD patients (Yang et al., 2012) and in smokers without
airflow obstruction (Barberà et al., 2001). In COPD, pulmonary
vasodilation can lead to deterioration of gas exchange due to
the high ventilation/perfusion ratio mismatch areas. Inhaled
prostanoids may acutely reduce pulmonary arterial pressure
while largely maintaining gas exchange; however, long-term
clinical trials have not been reported. Robust data for the clinical
beneficial effect of endothelin receptor antagonists (ERAs) on
pulmonary hemodynamics and exercise tolerance in COPD
with pulmonary hypertension are lacking. Finally, there is
definitely a lack of evidence of a long-term clinical beneficial
effect of PDE5 inhibitors in COPD patients (Seeger et al.,
2013), even if a recently published study demonstrated that
treatment with sildenafil is able to reduce pulmonary vascular
resistance and improve the BODE index (a multidimensional
grading system that predict mortality in COPD) and quality
of life, without a significant effect on gas exchange, in a
cohort of patients with severe pulmonary hypertension and
COPD (Vitulo et al., 2017). In this context, the result of
the present study, which demonstrates that sildenafil affects
the negative effects of hypoxia on right ventricle through
its impact on NO-pathway, may be of interest because one
can speculate a protective effect of sildenafil, or other drugs
active on the NO-pathway such as riociguat, on vessels
remodeling leading and pulmonary hypertension and right
ventricle hypertrophy.
CONCLUSIONS
In the described model of pulmonary hypertension induced
by chronic exposure to hypoxia, PDE-5 inhibition by sildenafil
contrasts the negative effects of hypoxia on pulmonary and
right ventricle remodeling. This action does not only encompass
the canonical vasomodulatory effect, but involves several cell
pathways. Although the human pathological model is certainly
more complex than that described here (for example, by
including marked pro-inflammatory issues), PDE-5 inhibition
may become an appreciable target for long-term treatment of
pulmonary hypertension, and perhaps also for the prevention of
this debilitating disease.
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